Actively Recruiting
Secondary Prevention of Venous Thromboembolism in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis (STREAM-Line Study)
Led by Ottawa Hospital Research Institute · Updated on 2025-05-30
330
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating a management strategy for patients with cancer who have catheter-related upper extremity deep vein thrombosis (DVT) after completing at least three months of therapeutic anticoagulation. The study aims to demonstrate that continuing a prophylactic dose of apixaban is safe during the period after acute treatment in this population. This trial is sponsored by the Ottawa Hospital Research Institute and is a phase 4 interventional study focused on secondary prevention of venous thromboembolism (VTE).
CONDITIONS
Brief Title
Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults 18 years or older with active cancer diagnosed or treated within the last 6 months, or with metastatic, recurrent, or progressive malignancy, ongoing anticancer therapy, or hematological malignancy not in complete remission
- Objectively confirmed catheter-related upper extremity deep vein thrombosis
- Treated with standard therapeutic anticoagulation for at least 3 months
- Able and willing to provide informed consent
You will not qualify if you...
- Active bleeding or any condition where anticoagulation is not safe
- Need for ongoing therapeutic anticoagulation for other reasons like atrial fibrillation or mechanical heart valve
- Anticoagulation stopped or reduced to prophylactic dose before enrollment except transition to apixaban dose for 3 days or less
- Known allergy or contraindication to apixaban, including pregnancy
- Taking strong inhibitors or inducers of cytochrome P450 3A4 and P-glycoprotein enzymes
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Ongoing after enrollment until catheter removal and cancer remission
Participants receive a prophylactic dose of apixaban (2.5 mg orally twice daily) starting at enrollment and continuing as long as either a central venous catheter or active cancer is present. Apixaban is stopped at the time of catheter removal and when cancer is in remission.
Visits at Day 90±14 and Day 180+14 by phone call or in person
Trial Site Locations
Total: 1 location
1
The Ottawa Hospital
Ottawa, Ontario, Canada, K1H 8L6
Actively Recruiting
Research Team
T
Tzu-Fei Wang, MD, MPH
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here